PT  - JOURNAL ARTICLE
AU  - C. Brandon Ogbunugafor
AU  - Miles Miller-Dickson
AU  - Victor A. Meszaros
AU  - Lourdes M. Gomez
AU  - Anarina L. Murillo
AU  - Samuel V. Scarpino
TI  - Variation in SARS-CoV-2 free-living survival and environmental transmission can modulate the intensity of COVID-19 outbreaks
AID  - 10.1101/2020.05.04.20090092
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.04.20090092
4099  - http://medrxiv.org/content/early/2020/06/09/2020.05.04.20090092.short
4100  - http://medrxiv.org/content/early/2020/06/09/2020.05.04.20090092.full
AB  - COVID-19 has circled the globe, rapidly expanding into a pandemic within a matter of weeks. While early studies revealed important features of SARS-CoV-2 transmission, the role of variation in free-living virus survival in modulating the dynamics of outbreaks remains unclear and controversial. Using an empirically determined understanding of the natural history of SARS-CoV-2 infection and detailed, country-level case data, we elucidate how variation in free-living virus survival influences key features of COVID-19 epidemics. Our findings suggest that environmental transmission can have a subtle, yet significant influence on COVID-19’s basic reproductive number () and other key signatures of outbreak intensity. Summarizing, we propose that variation in environmental transmission may explain some observed differences in disease dynamics from setting to setting, and can inform public health interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementALM would like to acknowledge NIH U54GM115677 for funding support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NoneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are either available or the source is referenced in the main text and supplemental information. The code used for the analyses in this study is publicly available on Github: https://github.com/OgPlexus/Copperland https://github.com/OgPlexus/Copperland